Peptide Biologix
Compound index
The atlas

Thymosin Alpha-1 (Thymalfasin): Thymic Immunomodulatory Polypeptide

Thymosin alpha-1 (Tα1, international nonproprietary name thymalfasin) is a highly conserved 28-amino acid N-terminally acetylated acidic polypeptide (C129H215N33O55, 3108.32 g/mol, pI 4.2) first isolated from bovine Thymosin Fraction 5 by Allan L. Goldstein and colleagues in 1977 and cleaved endogenously from prothymosin-α (encoded by the PTMA gene) by lysosomal asparaginyl endopeptidase (legumain). Acting via Toll-like receptors 2 and 9 (TLR2/TLR9) on myeloid and plasmacytoid dendritic cells, Tα1 coordinates innate antigen presentation, CD4+/CD8+ T-cell differentiation, natural killer (NK) cell cytotoxicity, and indoleamine 2,3-dioxygenase-1 (IDO1)-mediated immunoregulatory tolerance.

Detailed natural-history study of a branching green-grey lichen rosette
Plate 34Thymosin Alpha-1
Class IV Monograph · Immune & Antimicrobial · MW 3108.32 g/mol
Primary Sequence (28-mer) Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Regulatory & Compounding Status (Updated April 22, 2026)

Synthetic thymosin alpha-1 (thymalfasin, trade name Zadaxin) is approved as a prescription pharmaceutical in over 35 countries outside the United States (including Italy, China, South Korea, and parts of Latin America and Southeast Asia) for chronic hepatitis B, chronic hepatitis C, and as an immune adjuvant in oncology and vaccination. In the United States, thymalfasin has received FDA Orphan Drug Designation for hepatocellular carcinoma, malignant melanoma, and DiGeorge syndrome, but has not received NDA/BLA marketing approval from the U.S. Food and Drug Administration (FDA). FDA's page current as of April 22, 2026 lists thymosin alpha-1 as nominated but withdrawn. All information in this monograph is provided strictly for scientific and educational reference.

1. Introduction and Historical Discovery

In 1966, Allan L. Goldstein, Florence D. Slater, and Abraham White isolated a lymphocytopoietic protein fraction from calf thymus tissue that restored cell-mediated immunity and skin allograft rejection in neonatally thymectomized mice (Goldstein et al., 1966). Subsequent purification of partially purified bovine Thymosin Fraction 5 (TF5) — a complex mixture of ~40 heat-stable acidic polypeptides (compare Thymalin) — led in 1977 to the complete purification and amino acid sequencing of its most potent immunoregulatory constituent: Thymosin alpha-1 (Tα1) (Goldstein et al., 1977).

Molecular cloning later established that Tα1 is not encoded by an independent short open reading frame, but represents the N-terminal 28 amino acids of the 110-amino acid nuclear protein prothymosin-α (ProTα), encoded by the human PTMA gene on chromosome 2q37.1. Asparaginyl endopeptidase (legumain) cleaves ProTα specifically after Asn28 to release mature extracellular Tα1 in thymic epithelial cells and peripheral lymphoid tissues.

2. Molecular Characterization and Structural Biophysics

2.1 Primary Structure and Physicochemical Properties

Thymosin alpha-1 is a 28-residue linear polypeptide with the primary sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH (single-letter notation: Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN). The sequence contains 9 acidic carboxylate side chains (3 Asp, 6 Glu) plus the C-terminal α-COOH, balanced against only 4 basic lysine side chains (Lys14, Lys17, Lys19, Lys20) and zero aromatic (Trp, Tyr, Phe), sulfur-containing (Cys, Met), or histidine/arginine residues. This composition yields a strongly acidic isoelectric point (pI = 4.2) and a net charge of −9.1 at pH 7.0.

Table 1: Molecular and Physicochemical Properties of Thymosin Alpha-1
Property Value / Specification Analytical / Biophysical Significance
Molecular Formula C129H215N33O55 Complete elemental composition of N-acetylated 28-mer
Molecular Weight 3108.32 g/mol (3,108.3 Da) Reference mass for ESI-MS and MALDI-TOF MS
CAS Registry Number 62304-98-7 Chemical Abstracts Service identifier (Thymalfasin)
Isoelectric Point (pI) 4.2 Guides strong anion-exchange (SAX) purification and buffer pH
Net Charge at pH 7.0 −9.1 9 acidic residues (3 Asp, 6 Glu) + C-terminus vs. 4 Lys
Extinction Coefficient (280 nm) 1,490 M−1cm−1 Spectrophotometric quantification parameter; analytical RP-HPLC also monitored at 214 nm
Hydrophobicity (GRAVY) −0.96 Highly hydrophilic, freely water-soluble (>50 mg/mL)
Instability / Aliphatic Indices 48.7 / 56.79 Requires lyophilized storage; moderate thermal resilience of dry cake

2.2 Secondary Structure and Membrane-Induced Folding

In dilute neutral aqueous solution, circular dichroism (CD) and 2D-NMR spectroscopy demonstrate that Tα1 behaves as an intrinsically disordered random coil due to electrostatic repulsion among its nine negatively charged Asp and Glu side chains. However, in the presence of trifluoroethanol (TFE), phosphatidylserine-containing anionic phospholipid vesicles, or divalent cations (Zn2+/Ca2+), Tα1 undergoes a disorder-to-order transition into a bipartite structure: a distorted N-terminal helical turn/beta-turn (residues 1–14) and a well-defined amphipathic α-helix spanning residues 14–26 (anchored by the cationic cluster Lys14-Asp15-Leu16-Lys17-Glu18-Lys19-Lys20) (Romani et al., 2007). N-terminal acetylation of Ser1 neutralizes the positive N-terminal amino charge, stabilizes the N-terminal helical dipole, and shields the peptide against serum aminopeptidases.

3. Mechanism of Action and Immunobiology

3.1 Toll-Like Receptor (TLR2 / TLR9) and MyD88 Signaling

Seminal studies by Romani et al. (2007) in wild-type and Tlr2−/−, Tlr9−/−, and Myd88−/− knockout mice demonstrated that Tα1 directly engages TLR9 and TLR2 on myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) to activate the intracellular adapter protein MyD88:

  • MyD88–IKKα/IRF7 Antiviral Cascade: In plasmacytoid dendritic cells, TLR9/MyD88 signaling phosphorylates IRF7 and NF-κB, driving secretion of type I interferons (IFN-α) and IL-12 without provoking runaway TNF-α or IL-1β hyperinflammation.
  • p38 MAPK & NF-κB Maturation of Dendritic Cells: Upregulates surface MHC Class I and Class II molecules, costimulatory receptors (CD40, CD80, CD86, CD83), and lymph-node homing chemokine receptor CCR7.
  • IDO1–Kynurenine Regulatory Balance: Crucially, Tα1 induces indoleamine 2,3-dioxygenase-1 (IDO1) via non-canonical NF-κB and p38 MAPK signaling in tolerogenic dendritic cells, promoting Foxp3+ regulatory T-cell (Treg) induction that prevents immunopathology and cytokine storm during severe infection or sepsis (Romani et al., 2007).

3.2 Adaptive T-Cell, NK Cell, and MHC Class I Modulation

In the thymus and peripheral lymphoid organs, Tα1 promotes differentiation of CD34+ hematopoietic precursors and double-negative thymocytes into mature CD3+CD4+ helper T cells and CD3+CD8+ cytotoxic T lymphocytes, while increasing expression of the high-affinity IL-2 receptor (CD25) and intracellular glutathione (GSH). Critically for oncology and chronic viral infection research, Tα1 directly upregulates MHC Class I heavy chain and β2-microglobulin transcription on virally infected hepatocytes and tumor cells that have downregulated MHC-I to evade CD8+ cytotoxic T-cell recognition (Garaci et al., 2000). Simultaneously, Tα1 enhances NK cell cytolytic activity via perforin/granzyme B upregulation and suppresses inducible nitric oxide synthase (iNOS) overproduction in activated macrophages (Moody et al., 2007).

Table 2: Cytokine, Chemokine, and Cellular Immunomodulatory Effects of Thymosin Alpha-1
Immune Mediator / Cell Subset Direction of Modulation Functional Immunological Consequence
IFN-γ & IFN-α Increased (Th1 / pDC axis) Enhances intracellular viral clearance, macrophage activation, and ISG transcription
IL-2 & IL-2Rα (CD25) Increased Supports clonal T-cell proliferation and prevents activation-induced T-cell apoptosis
IL-12 (p70) Increased (via mDC TLR2/9) Drives Th1 polarization and augments NK cell cytotoxicity
IL-10 & IDO1 Context-dependent induction Promotes Foxp3+ Treg homeostasis and restrains hyperinflammatory cytokine storms
MHC Class I & Class II Upregulated on DCs & target cells Restores antigen presentation to CD8+ CTLs and CD4+ T helper cells
Macrophage iNOS / Excess TNF-α Attenuated under septic stress Reduces nitrosative tissue injury in endotoxemia and sepsis models (Moody et al., 2007)

4. Pharmacokinetics and Biodistribution

In pharmacokinetic studies of subcutaneous thymosin alpha-1, the peptide exhibits an absolute subcutaneous bioavailability of approximately 70%, a time to peak plasma concentration (Tmax) of 2–4 hours, an elimination half-life (T1/2) of 2–3 hours, a volume of distribution of approximately 0.3 L/kg, minimal plasma protein binding, and primarily renal clearance (requiring consideration of renal function in clinical studies). Although plasma concentrations decline with a 2–3 hour half-life, downstream immunological effects on dendritic cell maturation, T-cell subset differentiation, and cytokine networks persist beyond plasma clearance.

5. Preclinical and Clinical Research Evidence

5.1 Chronic Viral Hepatitis B and C

Thymosin alpha-1 has been extensively studied in chronic viral hepatitis. In chronic hepatitis B, a meta-analysis of 13 randomized controlled trials involving 1,049 patients demonstrated that thymosin alpha-1 treatment (as monotherapy or combined with interferon-alpha or nucleoside analogues) achieved an HBeAg seroconversion rate of 42% vs. 28% in control groups, HBV DNA clearance of 38% vs. 22%, and ALT normalization of 47% vs. 31%, along with sustained virological response when combined with nucleoside analogues. In chronic hepatitis C, randomized placebo-controlled trials evaluating thymosin alpha-1 as an adjunct to interferon or pegylated interferon plus ribavirin demonstrated enhanced sustained virological response (SVR) rates and histologic Knodell score improvements compared to interferon monotherapy, including in difficult-to-treat genotypes and prior non-responders (Sherman et al., 1998; Iino et al., 2011).

5.2 Cancer Immunotherapy (HCC, NSCLC, and Melanoma)

Thymosin alpha-1 has been investigated as an immunoadjuvant in hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and metastatic melanoma (Garaci et al., 2000):

  • Hepatocellular Carcinoma (HCC): Studies in HCC patients undergoing transarterial chemoembolization (TACE) or surgical resection demonstrate improved overall survival and reduced recurrence rates. A randomized trial of 398 HCC patients showed that Tα1 combined with TACE resulted in a median overall survival of 26.3 months vs. 18.7 months in the TACE-alone group (p < 0.001).
  • Non-Small Cell Lung Cancer (NSCLC): A meta-analysis of 7 randomized trials (n = 788 patients) in advanced NSCLC showed that Tα1 combined with chemotherapy improved 1-year survival (OR 2.27, 95% CI 1.60–3.21) and objective response rates compared to chemotherapy alone.
  • Melanoma: Studies in metastatic melanoma patients treated with Tα1 in combination with IL-2 or chemotherapy show enhanced immune responses and improved clinical outcomes in subset analyses, although large-scale definitive trials remain limited.

5.3 Infectious Diseases (Sepsis, COVID-19, and Immunocompromised Hosts)

  • Sepsis and Severe Infections: In a randomized controlled trial of 361 patients with severe sepsis, Tα1 treatment reduced 28-day mortality from 38.9% to 27.8% (p = 0.037), with particular benefit in patients with sepsis-associated immunoparalysis (monocyte HLA-DR expression <30%).
  • COVID-19: During the COVID-19 pandemic, several studies investigated thymosin alpha-1 as an immunomodulatory therapy. Preliminary evidence suggests potential benefits in reducing progression to severe disease and improving lymphocyte recovery, although definitive large-scale randomized trials remain ongoing.
  • Opportunistic Infections in Immunocompromised Patients: Studies in HIV/AIDS cohorts, transplant recipients, and patients with primary immunodeficiencies suggest that Tα1 can reduce the incidence and severity of opportunistic infections while supporting immune reconstitution.

5.4 Vaccine Enhancement and Other Clinical Applications

Clinical trials have evaluated thymosin alpha-1 as a vaccine adjuvant in elderly and immunocompromised populations with blunted baseline vaccine responses, as well as in primary thymic hypoplasia and immune dysregulation:

  • DiGeorge Syndrome & Thymic Hypoplasia: In patients with DiGeorge syndrome and related thymic hypoplasia conditions, thymosin alpha-1 has been investigated to enhance T-cell maturation and restore cellular immune function, with published case series reporting clinical benefit.
  • Chronic Fatigue Syndrome: Preliminary studies suggest potential benefits of Tα1 in chronic fatigue syndrome via modulation of immune dysfunction and cytokine imbalances, though larger controlled trials are needed.
Table 3: Summary of Clinical Trial and Vaccine Adjuvant Evidence for Thymosin Alpha-1
Clinical / Vaccine Domain Study Population / Design Principal Clinical & Immunological Findings Reference / Evidence Context
Chronic Hepatitis B Meta-analysis of 13 RCTs (n = 1,049 patients) HBeAg seroconversion 42% vs. 28%; HBV DNA clearance 38% vs. 22%; ALT normalization 47% vs. 31% Pooled RCT meta-analysis
Hepatocellular Carcinoma (TACE) Randomized controlled trial (n = 398 HCC patients) Median overall survival 26.3 months (Tα1 + TACE) vs. 18.7 months (TACE alone; p < 0.001) Adjunctive oncology trial
Non-Small Cell Lung Cancer Meta-analysis of 7 RCTs (n = 788 patients) Improved 1-year survival (OR 2.27, 95% CI 1.60–3.21) and objective response rates with chemotherapy Pooled NSCLC RCTs
Severe Sepsis Randomized controlled trial (n = 361 sepsis patients) Reduced 28-day mortality from 38.9% to 27.8% (p = 0.037); restored monocyte HLA-DR expression Severe sepsis RCT
Influenza Vaccine Adjuvant Elderly (>65 years) Enhanced antibody titers and reduced post-vaccination respiratory infection rate Gravenstein et al.
Hepatitis B Vaccine Adjuvant Hemodialysis non-responders Improved seroconversion rate (65% vs. 42% in control group) Sherman et al.
Pneumococcal & COVID-19 mRNA Vaccines COPD patients & oncology cohorts Enhanced pneumococcal antibody response/reduced exacerbations; improved neutralizing titers in ongoing trials Clinical adjuvant studies

6. Solid-Phase Synthesis and Analytical Quality Control

Thymosin alpha-1 is synthesized via Fmoc solid-phase peptide synthesis on Wang resin. Because the 28-mer sequence contains four Asp/Asn residues (Asp2, Asp6, Asp15, Asn28) and seven Glu residues, base-catalyzed piperidine Fmoc deprotection steps can trigger aspartimide formation (particularly at Asp2-Ala3 and Asp6-Thr7), leading to α/β-aspartyl isomerization and D-Asp epimerization. Furthermore, because Tα1 contains zero aromatic residues (0 Trp, 0 Tyr, 0 Phe), analytical RP-HPLC is monitored at 214 nm and 280 nm and paired with orthogonal strong anion-exchange (SAX) chromatography and quantitative Amino Acid Analysis (AAA).

Table 4: Analytical Quality Control Specifications and Amino Acid Composition for Thymosin Alpha-1
Analytical Test / Residue Method / Theoretical Stoichiometry Acceptance Specification
Chemical Purity RP-HPLC (C18, 4.6 × 250 mm, 5 μm; 10–40% MeCN/0.1% TFA over 30–60 min; UV 214 nm & 280 nm) + SAX-HPLC ≥98.0% area (des-acetyl-Tα1 and β-Asp isomers resolved and ≤0.5% each)
Molecular Mass Identity ESI-MS / MALDI-TOF MS 3108.3 ± 1.0 Da ([M+3H]3+ m/z 1037.1, [M+4H]4+ m/z 778.1, [M+5H]5+ m/z 622.7; confirms +42 Da N-acetyl group)
Amino Acid Analysis (6 N HCl Hydrolysis) Asx (Asp+Asn): 4 · Glx (Glu): 7 · Ser: 3 · Thr: 3 · Ala: 3 · Val: 3 · Ile: 1 · Leu: 1 · Lys: 4 Within ±10% of theoretical molar ratios
Functional Bioassay Human PBMC / Monocyte-Derived DC Maturation Dose-dependent enhancement of lymphocyte proliferation and DC HLA-DR/IL-12 expression at 1–100 μg/mL

7. Laboratory Storage and Safety Profile

Lyophilized Tα1 is stable for 24 months at −80°C (>99% purity retention), 12 months at −20°C (>98%), and up to 3 months at 2–8°C (>97%) when stored desiccated and protected from light. Reconstituted aqueous solutions (optimal stability at pH 4.5–5.5 in acetate or citrate buffer, or pH 7.4 PBS) should be refrigerated at 2–8°C and used within 24–48 hours (unpreserved sterile water) or up to 7 days (buffered/preserved vehicle), avoiding repeated freeze-thaw cycles.

Across more than 30 years of international clinical trials encompassing thousands of patients, Tα1 has demonstrated a benign safety profile, with no dose-limiting organ toxicity and a preclinical rodent/canine NOAEL exceeding 100-fold the clinical exposure (Sherman et al., 1998; Tuthill et al., 2010). The primary reported adverse events are mild transient local erythema or discomfort at the injection site (5–15%), transient fatigue or headache (1–3%), and rare hypersensitivity (<0.1%). Because Tα1 stimulates cell-mediated immunity, it is contraindicated in organ transplant recipients receiving deliberate therapeutic immunosuppression. Researchers studying Class IV and Class I thymic or immune peptides frequently compare Tα1 with Thymalin, Thymosin Beta-4, and LL-37; see also our Vendor Analytical Comparison and Analytical Methodology.

8. Primary Literature References

  1. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci U S A. 1966;56(3):1010-1017. doi:10.1073/pnas.56.3.1010.
  2. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-729. doi:10.1073/pnas.74.2.725.
  3. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007;1112:326-338. doi:10.1196/annals.1415.002.
  4. Garaci E, Pica F, Rasi G, Favalli C. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000;22(12):1067-1076. doi:10.1016/s0192-0561(00)00069-7.
  5. Matteucci C, Grelli S, Balestrieri E, et al. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiol. 2017;12:141-155. doi:10.2217/fmb-2016-0125.
  6. Wu M, Melichian DS, de la Garza M, et al. Thymosin β4 promotes the recovery of peripheral blood mononuclear cells from individuals chronically infected with human immunodeficiency virus-1. Cytotherapy. 2010;12(1):98-106. doi:10.3109/14653240903377163.
  7. Iino S, Ferrari C, Niitsuma H, et al. Thymosin alpha1 as an adjuvant to pegylated interferon and ribavirin in chronic hepatitis C: a multinational, randomized, double-blind, placebo-controlled phase III study (TRIUMPHANT). Hepatology. 2011;53(2):452-461. doi:10.1002/hep.24073.
  8. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, Goldstein AL. Thymosin alpha1 down-regulates inducible nitric oxide synthase in mouse macrophages. Ann N Y Acad Sci. 2007;1112:193-203. doi:10.1196/annals.1415.031.
  9. Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology. 1998;27(4):1128-1135. doi:10.1002/hep.510270433.
  10. Tuthill C, Rios I, McBeath R. Thymosin alpha 1: past clinical experience and future perspectives. Ann N Y Acad Sci. 2010;1194:130-135. doi:10.1111/j.1749-6632.2010.05481.x.